<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28345">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811316</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-2013-1-23</org_study_id>
    <nct_id>NCT01811316</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis</brief_title>
  <official_title>A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunstar Americas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunstar Americas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term efficacy and safety of lozenges
      containing probiotics in reducing gingivitis. The primary purpose of this study is to
      support claims from U.S. instructions for use (IFU) for GUM® PerioBalance®.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Modified Gingival Index (MGI)</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Bleeding on probing (BOP)</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plaque Index</measure>
    <time_frame>4, 12  and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Probing Depth</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Inflammatory Markers in Gingival Crevicular</measure>
    <time_frame>15 days, 4, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gingivitis</condition>
  <arm_group>
    <arm_group_label>Probiotics Lozenge (twice a day)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics Lozenge (once a day)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lozenge (once a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics Lozenge (twice a day)</arm_group_label>
    <arm_group_label>Probiotics Lozenge (once a day)</arm_group_label>
    <arm_group_label>Placebo Lozenge (once a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to read, understand and sign an Informed Consent form.

          -  Good general health as evidenced by the medical history.

          -  Between 18 and 65 years of age.

          -  Male or female.

          -  Minimum of 20 teeth, excluding crowns and third molar teeth.

          -  Mean whole mouth Modified Gingival Index of greater-than or equal to 2.0 at baseline.

          -  Willing to abstain from all oral hygiene procedures for 12-18 hours prior to clinical
             visits.

          -  Willing to abstain from eating and drinking in the morning of visits, only drinking
             water is allowed.

          -  Willing to abstain from interdental cleaning, chewing gums, oral whitening, mouth
             rinse and tobacco products for the study duration.

          -  Able to understand and follow study directions.

          -  No known history of allergy to dairy products or their ingredients, relevant to any
             ingredient in the test products as determined by the dental/medical professional
             monitoring the study.

        Exclusion Criteria

          -  Presence of orthodontic appliances.

          -  Intra-oral soft tissue lesions due to pathology or trauma

          -  Patients with aggressive periodontitis, acute necrotizing ulcerative gingivitis, or
             gross decay at discretion of PI.

          -  More than two sites with pocket depth &gt;5mm and concomitant attachment loss of &gt;2mm.

          -  Pregnant or lactating females or females of child bearing potential not using
             acceptable methods of birth control (hormonal, barriers or abstinence).

          -  Use of antibiotics within 3 months of enrollment

          -  History of drug use that is associated with gum overgrowth (i.e., Dilantin,
             nifedipine, etc)

          -  Chronic use of medication such as steroids, NSAIDs (more than 2-3 days/week),
             anti-coagulant medications, immunosuppressant medications or any other medications
             that in the opinion of the Investigator would interfere with the evaluation or
             confound interpretation of the study results.  Use of low dose of ASA (81 mg) is
             permitted.

          -  Unwilling to sign a confidentiality statement and/or return the test products.

          -  Medical condition which requires pre-medication prior to dental visits/procedures.

          -  Immune compromised individuals (HIV, AIDS, immunosuppressive drug therapy).

          -  Current use of probiotics or probiotic containing food (i.e., yogurt)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hatice Hasturk, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Forsyth Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Wilson, MPH</last_name>
    <phone>773-481-3327</phone>
    <email>marie.wilson@us.sunstar.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Forsyth Institute</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatice Hasturk, DDS, PhD</last_name>
      <phone>617-892-8499</phone>
    </contact>
    <investigator>
      <last_name>Hatice Hasturk, DDS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gingivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
